Collegium Pharmaceutical (COLL) Change in Accured Expenses (2014 - 2026)

Collegium Pharmaceutical's Change in Accured Expenses history runs 13 years deep, the most recent figure standing at -$4.2 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 76.51% year-over-year to -$4.2 million; the TTM figure through Mar 2026 stood at $4.0 million (up 106.96% YoY), while the FY2025 annual figure was -$9.5 million, up 75.98% from the prior year.
• Change in Accured Expenses was -$4.2 million for Q1 2026 at Collegium Pharmaceutical, down from $10.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $22.4 million in Q4 2024 to a low of -$62.9 million in Q3 2024.
• Historically, Change in Accured Expenses has averaged -$3.7 million across 5 years, with a median of -$821000.0 in 2022.
• Biggest YoY gain for Change in Accured Expenses was 1635.09% in 2025; the steepest drop was 2777.73% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $13.6 million in 2022, then plunged by 62.42% to $5.1 million in 2023, then jumped by 339.04% to $22.4 million in 2024, then plunged by 52.26% to $10.7 million in 2025, then slumped by 138.79% to -$4.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$4.2 million (Q1 2026), $10.7 million (Q4 2025), and -$8.1 million (Q3 2025), per Business Quant data.